- Home
- BRW vs ABEO Comparison
BRW vs ABEO Comparison
Compare BRW & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 307.5M |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BRW | ABEO |
|---|---|---|
| Price | $6.73 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 224.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | ★ N/A | $5.34 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $6.38 | $4.00 |
| 52 Week High | $8.49 | $7.54 |
Technical Indicators
Market Signals| Indicator | BRW | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 56.63 |
| Support Level | $6.64 | $5.24 |
| Resistance Level | $6.92 | $5.62 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 32.14 | 55.38 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.